Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

Dragana Nikolic, Angelo M Patti, Rosaria V Giglio, Roberta Chianetta, Giuseppa Castellino, Antonio Magán-Fernández, Roberto Citarrella, Nikolaos Papanas, Andrej Janez, Anca Pantea Stoian, Ali A Rizvi, Manfredi Rizzo, Dragana Nikolic, Angelo M Patti, Rosaria V Giglio, Roberta Chianetta, Giuseppa Castellino, Antonio Magán-Fernández, Roberto Citarrella, Nikolaos Papanas, Andrej Janez, Anca Pantea Stoian, Ali A Rizvi, Manfredi Rizzo

Abstract

Introduction: The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the effect of this agent on cardiometabolic parameters in subjects with T2DM varied in relation to the concomitant presence of obesity.

Methods: One hundred thirty-five subjects (78 men and 57 women; age: 62 ± 10 years) naïve to incretin-based therapies were treated with low-dose liraglutide (1.2 mg/day) as an add-on to metformin for 18 months. Patients were divided into two subgroups based on their body-mass index (BMI): (a) obese (BMI ≥ 30) and (b) non-obese (BMI < 30). Clinical and laboratory analyses were assessed at baseline and every 6 months.

Results: During follow-up, significant improvements were seen in both groups in fasting glycemia, glycated hemoglobin, waist circumference, and carotid intima-media thickness (cIMT), while body weight, BMI, total cholesterol, and low-density lipoprotein cholesterol decreased significantly in obese subjects only. Correlation analysis revealed that changes in subclinical atherosclerosis (assessed by cIMT) were associated with changes in triglycerides (r = 0.488, p < 0.0001) in the obese group only.

Conclusion: Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter. These findings reinforce the benefits of liraglutide for the cardiometabolic outcomes of obese patients with T2DM in the real-world setting. This has critical importance during the current pandemic, since patients with diabetes and obesity are exposed globally to the most severe forms of COVID-19, related complications, and death.

Trial registration: ClinicalTrials.gov identifier, NCT01715428.

Keywords: Cardiovascular risk; Carotid intima–media thickness; GLP-1; Incretins; Liraglutide; Obesity; Type 2 diabetes mellitus.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Correlation plot of the significant association between changes in carotid intima–media thickness and changes in triglycerides after 18 months of liraglutide therapy in obese patients

References

    1. World Health Organization. Diabetes. . Accessed online on 26 Sept 2021.
    1. Lind M, Wedel H, Rosengren A. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2016;374:788–789. doi: 10.1056/NEJMc1515130.
    1. World Health Organization. Obesity. . Accessed online on 26 Sept 2021.
    1. Lawson AA, Strong JA, Peattie P, Roscoe P, Gibson A. Comparison of fenfluramine and metformin in treatment of obesity. Lancet. 1970;2:437–441. doi: 10.1016/S0140-6736(70)90056-5.
    1. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188–1193. doi: 10.1056/NEJM199411033311803.
    1. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. doi: 10.7573/dic.212283.
    1. Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima–media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016;15:162. doi: 10.1186/s12933-016-0480-8.
    1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.
    1. Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, Rizvi AA, Cosentino F. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2814–2821. doi: 10.1016/j.bbadis.2018.05.012.
    1. Patel D, Smith A. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Rev Clin Pharmacol. 2021;7:1–12.
    1. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA, NN8022–1922 Study Group Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–699. doi: 10.1001/jama.2015.9676.
    1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, ViolanteOrtiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. doi: 10.1056/NEJMoa1411892.
    1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi: 10.1056/NEJMoa1603827.
    1. Mackowiak JI, Mack CD, Irwin DE, Zura R. Randomized clinical trial or real-world evidence: how historical events, public demand, and the resulting laws and regulations shaped the body of medical evidence. J Orthop Trauma. 2021;35:S17–21.
    1. Cardio-Metabolic Academy Europe East Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. Diabetes Res Clin Pract. 2021;172:108535. doi: 10.1016/j.diabres.2020.108535.
    1. Maranta F, Cianfanelli L, Rizzo M, Cianflone D. Filling the gap between guidelines and real world in the cardiovascular approach to the diabetic patients: the need for a call to action. Int J Cardiol. 2021;329:205–7.
    1. Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, Citarrella R, Corrado E, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima–media thickness in patients with type-2 diabetes: an 8-month prospective study. Diabetes Res Clin Pract. 2019;149:163–169. doi: 10.1016/j.diabres.2019.02.006.
    1. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395. doi: 10.2337/dc12-2480.
    1. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701.
    1. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–983. doi: 10.2337/db08-1193.
    1. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(–/–) mouse model. Diabetes Vasc Dis Res. 2013;10:353–360. doi: 10.1177/1479164113481817.
    1. Corrado E, Rizzo M, Coppola G, Muratori I, Carella M, Novo S. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. Coron Artery Dis. 2008;19:139–144. doi: 10.1097/MCA.0b013e3282f3fbde.
    1. Stepien M, Stepien A, Wlazel RN, Paradowski M, Rizzo M, Banach M, Rysz J. Predictors of insulin resistance in patients with obesity: a pilot study. Angiology. 2014;65:22–30. doi: 10.1177/0003319712468291.
    1. Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, Sams A, Knudsen LB, Raun K, Havel PJ. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes. 2010;59:2653–2661. doi: 10.2337/db09-1564.
    1. Hermansen K, Bækdal TA, Düring M, Pietraszek A, Mortensen LS, Jørgensen H, Flint A. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15:1040–1048. doi: 10.1111/dom.12133.
    1. Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR, Borén J. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21:84–94. doi: 10.1111/dom.13487.
    1. Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol. 2014;13:135. doi: 10.1186/s12933-014-0135-6.
    1. Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2015;35:1880–1888. doi: 10.1161/ATVBAHA.115.305415.
    1. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B–17B. doi: 10.1016/S0002-9149(98)00032-0.
    1. Rizzo M, Berneis K. Who needs to care about small, dense low density lipoproteins? Int J Clin Pract. 2007;61:1949–1956. doi: 10.1111/j.1742-1241.2007.01596.x.
    1. Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract. 2009;63:56–62. doi: 10.1111/j.1742-1241.2008.01897.x.
    1. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, Sabuncu T, Karaman A, Cesur M, Rizzo M, Toth PP, Gedik V. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8:206–216. doi: 10.1016/j.jacl.2013.12.011.
    1. Rizzo M, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis. 2008;197:237–241. doi: 10.1016/j.atherosclerosis.2007.03.034.
    1. Goedecke JH, Utzschneider K, Faulenbach MV, Rizzo M, Berneis K, Spinas GA, Dave J, Levitt NS, Lambert EV, Olsson T, Kahn SE. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism. 2010;59:1341–50.
    1. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis. 2009;207:502–506. doi: 10.1016/j.atherosclerosis.2009.07.015.
    1. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, Isenovic ER. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20:4961–4969. doi: 10.2174/1381612819666131206103102.
    1. Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Atherosclerosis. 2019;288:60–66. doi: 10.1016/j.atherosclerosis.2019.07.007.
    1. Nikolic D, Giglio RV, Rizvi AA, Patti AM, Montalto G, Maranta F, Cianflone D, Stoian AP, Rizzo M. Liraglutide reduces carotid intima–media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: a novel anti-atherogenic effect. Diabetes Ther. 2021;12:261–274. doi: 10.1007/s13300-020-00962-3.
    1. Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother. 2008;9:343–349. doi: 10.1517/14656566.9.3.343.
    1. Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, Hirano T. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides. 2014;54:19–26. doi: 10.1016/j.peptides.2013.12.015.
    1. Stoian AP, Banerjee Y, Rizvi AA, Rizzo M. Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management. Metab Syndr Relat Disord. 2020;18:173–175. doi: 10.1089/met.2020.0037.
    1. Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M, CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO) Promoting a syndemic approach for cardiometabolic disease management during COVID-19: the CAPISCO international expert panel. Front Cardiovasc Med. 2021;8:787761. doi: 10.3389/fcvm.2021.787761.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren